MDXHealth SA (NASDAQ:MXDHF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Saturday.

According to Zacks, “MDxHealth SA is a healthcare company which provides actionable molecular diagnostic information for diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation and other molecular technologies and assist physicians with the diagnosis of cancer. MDxHealth SA is headquartered in Herstal, Belgium. “

Shares of MDXHealth SA (NASDAQ MXDHF) opened at 5.90 on Friday. The stock has a 50 day moving average of $5.75 and a 200-day moving average of $5.67. The stock’s market cap is $294.70 million. MDXHealth SA has a 52 week low of $4.46 and a 52 week high of $6.15.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/16/mdxhealth-sa-mxdhf-downgraded-to-hold-at-zacks-investment-research.html.

Get a free copy of the Zacks research report on MDXHealth SA (MXDHF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MDXHealth SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDXHealth SA and related companies with MarketBeat.com's FREE daily email newsletter.